PLTR vs REGN · P/E 584, rev $4.48B vs P/E 14, rev $14.34B
Palantir Technologies Inc. Class A Common Stock (PLTR) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Palantir Technologies Inc. Class A Common Stock (PLTR) is a software - infrastructure company listed on US. It is led by Alex Karp.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported PLTR revenue for 2025-12-31 was $4.48B. Net income was $1.63B. Revenue was up 56.2% from 2024-12-31 to 2025-12-31. PLTR currently screens at market cap $317.08B and trailing P/E 584.2.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
PLTR currently screens at market cap $317.08B and trailing P/E 584.2. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the PLTR and REGN stock pages for the full models.
Not investment advice.